 | | Vol. 5.32 – 27 August, 2021 |
| |
|
|
| Researchers performed integrative analyses combining copy number alterations (CNAs) with the transcriptomic data to reveal the cis- and trans-effects of CNAs in hepatocellular carcinoma.
[Science Advances] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists showed that upon starvation hepatic p53 was stabilized by O-GlcNAcylation and played an essential role in the physiological regulation of glucose homeostasis.
[Nature Communications] |
|
|
|
| Investigators identified a functional RNA – hsa_circ_0000384 (circMRPS35) from public tumor databases using a set of computational analyses, and further identified that circMRPS35 was highly expressed in 35 pairs of hepatocellular carcinoma from patients.
[Molecular Therapy] |
|
|
|
| Liver cells with disordered tyrosine catabolism, as exemplified by the suppression of a tyrosine catabolic enzyme 4-hydroxyphenylpyruvate dioxygenase (HPD), displayed augmented tumorigenic and proliferative potentials.
[Cell Reports] |
|
|
|
| The authors used an integrated epigenome and transcriptome analysis of mouse non-alcoholic fatty liver disease (NAFLD) hepatocytes and identified alterations in glyoxylate metabolism, a pathway relevant in kidney damage via oxalate release—a harmful waste product and kidney stone-promoting factor.
[Cell Reports] |
|
|
|
| Studying Sirt1 liver-specific knockout mice in combination with diethylnitrosamine (DEN) treatment, investigators demonstrated that loss of Sirt1 rendered mice resistant to DEN-induced hepatocellular carcinoma development.
[Oncogene] |
|
|
|
| Researchers demonstrated that ubiquitin-specific protease14 (USP14) was highly expressed in hepatocellular carcinoma samples, and the higher expression of USP14 was positively correlated with poor prognosis.
[Cell Death & Disease] |
|
|
|
| Circ_0057558 acted as a miR-206 sponge to de-repress the ROCK1/AMPK signaling and facilitated lipogenesis and triglyceride secretion, which greatly contributed to nonalcoholic fatty liver disease development and progression.
[Cell Death & Disease] |
|
|
|
| Scientists showed that BEX2, which is essential for dormant cancer stem cells in cholangiocarcinoma, was highly expressed in human hepatocellular carcinoma (HCC) lesions compared to the adjacent normal lesions, and that in 41 HCC cases the BEX2high expression group was correlated with a poor prognosis.
[Cancer Science] |
|
|
|
| PPARα activation enhanced the fatty acid β-oxidation, oxidative phosphorylation, and adenosine triphosphate production, thus promoting proliferation and differentiation of Sox9+ hepatocytes along periportal—perivenous axis.
[iScience] |
|
|
|
| The authors established human and mouse hepatocellular carcinoma cells with exon 3 skipping of β-catenin, which promoted nuclear translocation and activated the Wnt/β-catenin signaling pathway, by using newly developed multiplex CRISPR/Cas9-based genome engineering system.
[Scientific Reports] |
|
|
|
| In vitro, RAW264.7 cells were treated with lipopolysaccharides to induce macrophage polarization to the M1 phenotype, and they were co-cultured with WB-F344 cells and allocated to M group, YGJ group and WIF-1 group with untreated cells as control.
[Pharmaceutical Biology] |
|
|
|
| Human hepatic carcinoma cell lines were treated with different concentrations of myristicin for 24, 48 and 72 hours. Then tetrazolium assay, flow cytometer analysis and transwell assay were performed to determine cell proliferation, apoptosis and migration/invasion.
[Pharmaceutical Biology] |
|
|
|
|
| To fully and comprehensively understand the regulatory role of endoplasmic reticulum stress in the occurrence and progression of hepatocellular carcinoma, it is of vital importance to explore its pathogenesis and develop novel anti-cancer strategies.
[Biomedicine & Pharmacotherapy] |
|
|
|
| The authors summarize the emerging and more established therapeutic options considering the complex pathophysiology of nonalcoholic fatty liver disease and the important long-term sequelae of this condition.
[Clinical therapeutics] |
|
|
|
|
| Genevant Sciences announced that it has entered into a global collaboration and license agreement with Takeda Pharmaceutical Company Limited for the development and commercialization of novel nonviral gene therapies to treat up to two undisclosed rare liver diseases.
[Genevant Sciences] |
|
|
|
|
|
|
|
| | Sidney Kimmel Cancer Center at Jefferson Health – Philadelphia, Pennsylvania, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| University of Luxembourg – Luxembourg City, Luxembourg |
|
|
|
| | Purdue University – West Lafayette, Indiana, United States |
|
|
|
| | Amgen – San Francisco, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
